Transdermal Estradiol for Treatment of Schizophrenia in Women

One of the top causes of disability across the globe, schizophrenia can significantly diminish educational, occupational and psychosocial performance, impairing the lives of millions of people worldwide. Although the severe chronic neurological disorder affects a small proportion of the population – around 1% – it is one of the most disabling conditions, especially if left untreated. Schizophrenia carries a substantial disease burden; people with the disorder face increased risks of premature mortality, suicide, and physical illness.

While research has yet to identify a definitive cause of schizophrenia, many factors are thought to contribute to the development of schizophrenia, including genetics, environment, and neurological changes. Previous research implicates that estrogen may play a significant role in the condition’s progression, with a prior randomized controlled trial revealing symptom improvement in premenopausal female patients treated with transdermal estradiol. These initial positive findings have not been replicated by other studies, including ones without commercial involvement.

Continue reading

Alarming Rates of Life-Threatening Patient Nondisclosures

A patient’s full disclosure of medically relevant information to their clinician is essential to ensuring all-encompassing health support, developing successful treatment strategies and guaranteeing optimal outcomes. This is especially true in cases of imminent threat, which range from drug and substance abuse habits to domestic violence incidents. Previous research has revealed that patients often choose not to share details about certain behaviors, such as lack of exercise or poor diet, in fear of being judged or reprimanded. However, relatively little knowledge was available thus far about the disclosure rates for life-threatening factors.

While it is essential for primary care providers to be aware of all details affecting patient health, a recent study indicates that nearly half of patients withhold potentially life-threatening information from their physicians. Aiming to determine the prevalence of patient nondisclosure about imminent threats and identify the common underlying reasons, researchers evaluated data from 4,510 Amazon’s Mechanical Turk (MTurk) and Survey Sampling International (SSI) survey respondents.

Continue reading

National Alzheimer’s Disease Month: The Connection between Alzheimer’s Disease and Diabetes

Celebrated as National Alzheimer’s Disease Month, the month of November is recognized as a nationwide opportunity to raise awareness for those afflicted with the disease. Currently, there are an estimated 5.8 million Americans living with Alzheimer’s disease (AD) – the 6th leading cause of death in the nation. Alzheimer’s disease has seen a dramatic increase in mortality rate of 145% since the year 2000 and continues to grow in incidence.

Although AD mostly affects individuals over the age of 65, early-onset Alzheimer’s may be more prevalent than previously thought, occurring at a rate of close to 6%, rather than the 1-2% rate presumed from prior studies. The number of Americans suffering from Alzheimer’s is growing quickly; projections forecast that by 2050 the number of people living with AD in the United States will grow to approximately 14 million.

Continue reading